ClinicalTrials.gg
CompletedNCT02984995Updated Feb 17, 2020Results posted

Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

A Phase 2 interventional study of Quizartinib in Leukemia, Myeloid, Acute, sponsored by Daiichi Sankyo Co., Ltd.. Completed at 27 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-02-17.

Sponsored by Daiichi Sankyo Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing quizartinib in Leukemia, Myeloid, Acute — 6 open to participants now, 10 under way, 2 of them phase 3. quizartinib · Leukemia, Myeloid, Acute.

Enrollment
20th of 28
37 · median 69
Started
2016
with 3 others
Phase 2
7 of 28
3 open now
Registered
11th of 28
by date
Lead sponsor
4 of 28
Daiichi Sankyo Co., Ltd.

Among the 28 studies testing quizartinib in Leukemia, Myeloid, Acute, this one is the 20th largest by enrollment, is one of 4 that started in 2016, is one of 7 in phase 2, and was the 11th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

6 of the 28 studies testing quizartinib in Leukemia, Myeloid, Acute are open now, in 9 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About quizartinib

quizartinib: first FDA approval 2023 (VANFLYTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing quizartinib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This is a Phase 2, multi-center, open-label study to evaluate the efficacy, safety and pharmacokinetics of quizartinib monotherapy in Japanese subjects with FLT3-ITD positive refractory or relapsed acute myeloid leukemia.

03

Conditions studied

  • Leukemia, Myeloid, Acute

Keywords

  • FLT3-ITD
  • Positive refractory or relapsed acute myeloid leukemia
  • Hematology malignancy
  • Developmental Phase II
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • AML patients in first relapse or after all prior therapy
  • Presence of the FLT3-ITD activating mutation in bone marrow or peripheral blood
  • (ECOG) Performance Status (PS) of 0 to 2

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of acute promyelocytic leukemia
  • AML secondary to prior chemotherapy for other neoplasms.
  • Persistent, > Grade 1 non-hematologic toxicity from prior AML therapy
  • Prior treatment with a FLT3 targeted therapy
  • Active infection not well controlled by antibacterial, antifungal and/or antiviral therapy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Initial dose 30 mg/day quizartinib

    Participants who received an initial dose of 30 mg/day of quizartinib and, if no QT prolongation, the dose escalated to 60 mg/day at Day 15.

    Drug: Quizartinib

  • Experimental
    Initial dose 20 mg/day quizartinib

    Participants who received a CYP3A4 strong inhibitor received an initial dose of 20 mg/day of quizartinib and, if no QT prolongation, the dose escalated to 30 mg/day at Day 15.

    Drug: Quizartinib

Interventions

  • Quizartinib was orally administered once daily every morning. Treatment with quizartinib was administered in 28-day cycles and continued until the discontinuation criteria for treatment were met.

06

What researchers measure

Primary outcomes

  1. Composite Complete Remission (CRc) Rate After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML

    The composite complete remission (CRc) rate is defined as the proportion of participants whose best response is complete remission \[CR\], CR with incomplete platelet recovery \[CRp\], or CR with incomplete hematological recovery \[CRi\]) after treatment with quizartinib.

    Time frame: Baseline, cycle 2 day 1, cycle 3 day 1, cycle 4 day 1 up until the end of treatment, except for responses from any subsequent AML therapy including transplantation

Secondary outcomes

  1. Best Response After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML

    Best response is defined as the best measured response over all response assessments (complete response \[CR\], CR with incomplete platelet recovery \[CRp\], CR with incomplete hematological recovery \[CRi\], partial remission \[PR\], no response \[NR\], or Unknown) at all time points after the first dose of the study drug to the end of treatment (does not include response from any subsequent AML therapy including transplantation).

    Time frame: Baseline, cycle 2 day 1, cycle 3 day 1, cycle 4 day 1 until the end of treatment, except for responses from any subsequent AML

  2. Response Rate After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML

    Time frame: Baseline, cycle 2 day 1, cycle 3 day 1, cycle 4 day 1 until the end of treatment, except for responses from any subsequent AML

  3. Duration of Composite Complete Remission (CRc) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML

    Duration from the date of first composite complete remission (CRc) (complete remission \[CR\], CR with incomplete platelet recovery \[CRp\], or CR with incomplete hematological recovery \[CRi\]) observed to the date of documented relapse was assessed.

    Time frame: Baseline, cycle 2 day 1, cycle 3 day 1, cycle 4 day 1 up until the end of treatment, except for responses from any subsequent AML therapy including transplantation

  4. Overall Survival (OS) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML

    OS is defined as the time from registration (enrollment) until death from any cause.

    Time frame: Baseline, cycle 2 day 1, cycle 3 day 1, cycle 4 day 1 until the end of treatment, except for responses from any subsequent AML therapy including transplantation up to 1 year

  5. Event-free Survival (EFS) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML

    Event-free survival is defined as the time from date of registration until documented refractory disease, relapse after response of composite complete remission (CRc = complete remission \[CR\], CR with incomplete platelet recovery \[CRp\], or CR with incomplete hematological recovery \[CRi\]), or death from any cause, whichever occurs first.

    Time frame: Baseline, cycle 2 day 1, cycle 3 day 1, cycle 4 day 1 until the end of treatment, except for responses from any subsequent AML therapy including transplantation up to 32 weeks

  6. Leukemia-free Survival (LFS) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML

    Leukemia-free survival (LFS) is the time from the first documented response of CRc until documented relapse or death from any cause. The analysis for LFS will be conditional on the participant having a documented best response of CRc.

    Time frame: Baseline, cycle 2 day 1, cycle 3 day 1, cycle 4 day 1 until the end of treatment, except for responses from any subsequent AML therapy including transplantation up to 28 weeks

  7. Hematopoietic Stem Cell Transplantation Rate After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML

    Proportion of participants who start hematopoietic stem cell transplantation (HSCT) immediately after the end of treatment with the study drug without receiving other treatment for AML, except for conditioning regiment for HSCT, was assessed.

    Time frame: Up to new AML treatment or 1 year post treatment

  8. Change in the Area Under the Plasma Concentration Time Curve (AUC) of Quizartinib and Its Active Metabolite After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML

    Time frame: Cycle 1, Days 1 and 15; Cycle 2, Day 1

  9. Change in the Maximum Plasma Concentration (Cmax) of Quizartinib and Its Metabolite (AC886) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML

    Time frame: Cycle 1, Days 1 and 15; Cycle 2, Day 1

  10. Change in the Trough Plasma Concentration (Ctrough) of Quizartinib and Its Metabolite (AC886) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML

    Time frame: Cycle 1, Day 15

  11. Change in the Time to Reach Maximum Plasma Concentration (Tmax) of Quizartinib and Its Metabolite (AC886) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML

    Time frame: Cycle 1, Days 1 and 15; Cycle 2, Day 1

07

Results

Posted Feb 17, 2020

Participant flow

A total of 37 participants who met all inclusion and no exclusion criteria were enrolled in the study.

Participant flow — Overall Study
MilestoneInitial Dose 30 mg/Day QuizartinibInitial Dose 20 mg/Day Quizartinib
Started343
Completed90
Not completed253
Withdrew: Required stem cell transplant132
Withdrew: Progressive disease111
Withdrew: Adverse event10

Outcome measures

PrimaryComposite Complete Remission (CRc) Rate After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML

The composite complete remission (CRc) rate is defined as the proportion of participants whose best response is complete remission \[CR\], CR with incomplete platelet recovery \[CRp\], or CR with incomplete hematological recovery \[CRi\]) after treatment with quizartinib.

Time frame:
Baseline, cycle 2 day 1, cycle 3 day 1, cycle 4 day 1 up until the end of treatment, except for responses from any subsequent AML therapy including transplantation
Reported as:
Number · percentage of participants
Composite Complete Remission (CRc) Rate After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
percentage of participantsInitial Dose 30 mg/Day QuizartinibInitial Dose 20 mg/Day QuizartinibTotal
Composite Complete Remission (CRc) Rate After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML56.5 (37.5 to 74.2)33.3 (1.7 to 86.5)53.8 (36.2 to 70.8)
SecondaryBest Response After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML

Best response is defined as the best measured response over all response assessments (complete response \[CR\], CR with incomplete platelet recovery \[CRp\], CR with incomplete hematological recovery \[CRi\], partial remission \[PR\], no response \[NR\], or Unknown) at all time points after the first dose of the study drug to the end of treatment (does not include response from any subsequent AML therapy including transplantation).

Time frame:
Baseline, cycle 2 day 1, cycle 3 day 1, cycle 4 day 1 until the end of treatment, except for responses from any subsequent AML
Reported as:
Count of participants · Participants
Best Response After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
ParticipantsInitial Dose 30 mg/Day QuizartinibInitial Dose 20 mg/Day QuizartinibTotal
Complete response (CR)000
Complete response with incomplete platelet (CRp)101
Complete response with incomplete hematologic(CRi)12113
Partial remission (PR)617
No response (NR)516
SecondaryResponse Rate After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
Time frame:
Baseline, cycle 2 day 1, cycle 3 day 1, cycle 4 day 1 until the end of treatment, except for responses from any subsequent AML
Reported as:
Number · percentage of participants
Response Rate After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
percentage of participantsInitial Dose 30 mg/Day QuizartinibInitial Dose 20 mg/Day QuizartinibTotal
Response Rate After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML79.2 (57.8 to 92.9)66.7 (9.4 to 99.2)77.8 (57.7 to 91.4)
SecondaryDuration of Composite Complete Remission (CRc) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML

Duration from the date of first composite complete remission (CRc) (complete remission \[CR\], CR with incomplete platelet recovery \[CRp\], or CR with incomplete hematological recovery \[CRi\]) observed to the date of documented relapse was assessed.

Time frame:
Baseline, cycle 2 day 1, cycle 3 day 1, cycle 4 day 1 up until the end of treatment, except for responses from any subsequent AML therapy including transplantation
Reported as:
Median · weeks
Duration of Composite Complete Remission (CRc) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
weeksInitial Dose 30 mg/Day QuizartinibInitial Dose 20 mg/Day QuizartinibTotal
Duration of Composite Complete Remission (CRc) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML16.1 (4.7 to 24.6)NA (NA to NA)16.1 (4.7 to 24.6)
SecondaryOverall Survival (OS) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML

OS is defined as the time from registration (enrollment) until death from any cause.

Time frame:
Baseline, cycle 2 day 1, cycle 3 day 1, cycle 4 day 1 until the end of treatment, except for responses from any subsequent AML therapy including transplantation up to 1 year
Reported as:
Median · weeks
Overall Survival (OS) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
weeksInitial Dose 30 mg/Day QuizartinibInitial Dose 20 mg/Day QuizartinibTotal
Overall Survival (OS) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML34.1 (27.1 to NA)NA (22.6 to NA)34.1 (27.1 to NA)
SecondaryEvent-free Survival (EFS) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML

Event-free survival is defined as the time from date of registration until documented refractory disease, relapse after response of composite complete remission (CRc = complete remission \[CR\], CR with incomplete platelet recovery \[CRp\], or CR with incomplete hematological recovery \[CRi\]), or death from any cause, whichever occurs first.

Time frame:
Baseline, cycle 2 day 1, cycle 3 day 1, cycle 4 day 1 until the end of treatment, except for responses from any subsequent AML therapy including transplantation up to 32 weeks
Reported as:
Median · weeks
Event-free Survival (EFS) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
weeksInitial Dose 30 mg/Day QuizartinibInitial Dose 20 mg/Day QuizartinibTotal
Event-free Survival (EFS) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML12.7 (0.1 to 24.7)0.1 (0.1 to NA)12.7 (0.1 to 24.7)
SecondaryLeukemia-free Survival (LFS) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML

Leukemia-free survival (LFS) is the time from the first documented response of CRc until documented relapse or death from any cause. The analysis for LFS will be conditional on the participant having a documented best response of CRc.

Time frame:
Baseline, cycle 2 day 1, cycle 3 day 1, cycle 4 day 1 until the end of treatment, except for responses from any subsequent AML therapy including transplantation up to 28 weeks
Reported as:
Median · weeks
Leukemia-free Survival (LFS) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
weeksInitial Dose 30 mg/Day QuizartinibInitial Dose 20 mg/Day QuizartinibTotal
Leukemia-free Survival (LFS) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML16.1 (4.7 to 24.6)NA (NA to NA)16.1 (4.7 to 24.6)
SecondaryHematopoietic Stem Cell Transplantation Rate After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML

Proportion of participants who start hematopoietic stem cell transplantation (HSCT) immediately after the end of treatment with the study drug without receiving other treatment for AML, except for conditioning regiment for HSCT, was assessed.

Time frame:
Up to new AML treatment or 1 year post treatment
Reported as:
Number · Percentage of participants
Hematopoietic Stem Cell Transplantation Rate After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
Percentage of participantsInitial Dose 30 mg/Day QuizartinibInitial Dose 20 mg/Day QuizartinibTotal
Hematopoietic Stem Cell Transplantation Rate After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML37.9 (20.7 to 57.7)33.3 (0.8 to 90.6)37.5 (21.1 to 56.3)
SecondaryChange in the Area Under the Plasma Concentration Time Curve (AUC) of Quizartinib and Its Active Metabolite After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
Time frame:
Cycle 1, Days 1 and 15; Cycle 2, Day 1
Reported as:
Mean · ng*h/mL
Change in the Area Under the Plasma Concentration Time Curve (AUC) of Quizartinib and Its Active Metabolite After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
ng*h/mLQuizartinib 20 mg/Day (With Use of Strong CYP3A4 Inhibitor)Quizartinib 30 mg/Day (With No Use of Strong CYP3A4 Inhibitor)Quizartinib 30 mg/Day (With Use of Strong CYP3A4 Inhibitor)Quizartinib 60 mg/Day (With No Use of Strong CYP3A4 Inhibitor)
Cycle 1, Day 1; Quizartinib (n=3,34,0,0)877 ± 4891170 ± 716——
Cycle 1, Day 1; Active Metabolite (n=3,34,0,0)75.1 ± 80.6560 ± 391——
Cycle 1, Day 15; Quizartinib (n=3,32,0,0)2610 ± 6933970 ± 2610——
Cycle 1, Day 15; Active Metabolite (n=3,32,0,0)430 ± 2763120 ± 1300——
Cycle 2, Day 1; Quizartinib (n=0,0,2,21)——2960 ± 7499240 ± 6090
Cycle 2, Day 1; Active Metabolite (n=0,0,2,21)——983 ± 3896530 ± 2630
SecondaryChange in the Maximum Plasma Concentration (Cmax) of Quizartinib and Its Metabolite (AC886) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
Time frame:
Cycle 1, Days 1 and 15; Cycle 2, Day 1
Reported as:
Mean · ng/mL
Change in the Maximum Plasma Concentration (Cmax) of Quizartinib and Its Metabolite (AC886) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
ng/mLQuizartinib 20 mg/Day (With Use of Strong CYP3A4 Inhibitor)Quizartinib 30 mg/Day (With No Use of Strong CYP3A4 Inhibitor)Quizartinib 30 mg/Day (With Use of Strong CYP3A4 Inhibitor)Quizartinib 60 mg/Day (With No Use of Strong CYP3A4 Inhibitor)
Cycle 1, Day 1; Quizartinib (n=3,34,0,0)48.1 ± 25.976.9 ± 46.8——
Cycle 1, Day 1; Active Metabolite (n=3,34,0,0)3.92 ± 4.4929.1 ± 20.9——
Cycle 1, Day 15; Quizartinib (n=3,32,0,0)127 ± 35.9211 ± 132——
Cycle 1, Day 15; Active Metabolite (n=3,32,0,0)18.9 ± 12.1146 ± 60.4——
Cycle 2, Day 1; Quizartinib (n=0,0,2,21)——149 ± 38.2480 ± 296
Cycle 2, Day 1; Active Metabolite (n=0,0,2,21)——43.7 ± 17.7298 ± 118
SecondaryChange in the Trough Plasma Concentration (Ctrough) of Quizartinib and Its Metabolite (AC886) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
Time frame:
Cycle 1, Day 15
Reported as:
Mean · ng/mL
Change in the Trough Plasma Concentration (Ctrough) of Quizartinib and Its Metabolite (AC886) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
ng/mLQuizartinib 20 mg/Day (With Use of Strong CYP3A4 Inhibitor)Quizartinib 30 mg/Day (With No Use of Strong CYP3A4 Inhibitor)Quizartinib 30 mg/Day (With Use of Strong CYP3A4 Inhibitor)Quizartinib 60 mg/Day (With No Use of Strong CYP3A4 Inhibitor)
Cycle 1, Day 15; Quizartinib98.2 ± 19.7128 ± 92.5——
Cycle 1, Day 15; Active Metabolite17.8 ± 11.3112 ± 47.9——
SecondaryChange in the Time to Reach Maximum Plasma Concentration (Tmax) of Quizartinib and Its Metabolite (AC886) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
Time frame:
Cycle 1, Days 1 and 15; Cycle 2, Day 1
Reported as:
Median · h
Change in the Time to Reach Maximum Plasma Concentration (Tmax) of Quizartinib and Its Metabolite (AC886) After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML
hQuizartinib 20 mg/Day (With Use of Strong CYP3A4 Inhibitor)Quizartinib 30 mg/Day (With No Use of Strong CYP3A4 Inhibitor)Quizartinib 30 mg/Day (With Use of Strong CYP3A4 Inhibitor)Quizartinib 60 mg/Day (With No Use of Strong CYP3A4 Inhibitor)
Cycle 1, Day 1; Quizartinib (n=3,34,0,0)4.08 (2.17 to 6.17)4.03 (1.85 to 24.20)——
Cycle 1, Day 1; Active Metabolite (n=2,33,0,0)24.33 (24.25 to 24.42)24.32 (3.93 to 24.67)——
Cycle 1, Day 15; Quizartinib (n=3,32,0,0)4.08 (4.08 to 6.25)3.06 (1.42 to 6.08)——
Cycle 1, Day 15; Active Metabolite (n=3,32,0,0)4.08 (0 to 6.25)5.82 (0.83 to 24.50)——
Cycle 2, Day 1; Quizartinib (n=0,0,2,21)——6.17 (6.08 to 6.24)3.87 (0 to 6.23)
Cycle 2, Day 1; Active Metabolite (n=0,0,2,21)——14.17 (4.25 to 24.08)5.65 (0 to 24.02)

Adverse events

Collected over Adverse events were collected from the signing of the informed consent form through 45 days after last dose of study drug up to approximately 2 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Initial Dose 30 mg/Day Quizartinib13/34 (38.2%)14/34 (41.2%)34/34 (100%)
Initial 20 mg/Day Quizartinib1/3 (33.3%)3/3 (100%)3/3 (100%)
Total14/37 (37.8%)17/37 (45.9%)37/37 (100%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventInitial Dose 30 mg/Day QuizartinibInitial 20 mg/Day QuizartinibTotal
Febrile neutropeniaBlood and lymphatic system disorders4/342/36/37
SepsisInfections and infestations1/341/32/37
NeutropeniaBlood and lymphatic system disorders0/341/31/37
BacteremiaInfections and infestations2/340/32/37
CellulitisInfections and infestations1/340/31/37
EncephalitisInfections and infestations1/340/31/37
PneumoniaInfections and infestations1/340/31/37
AnemiaBlood and lymphatic system disorders1/340/31/37
Disseminated intravascular coagulationBlood and lymphatic system disorders1/340/31/37
HematomaVascular disorders1/340/31/37
Most frequent other events
Showing 10 of 45
Most frequent other events
EventInitial Dose 30 mg/Day QuizartinibInitial 20 mg/Day QuizartinibTotal
NauseaGastrointestinal disorders9/342/311/37
Transfusion reactionInjury, poisoning and procedural complications0/342/32/37
Platelet count decreasedInvestigations13/340/313/37
Electrocardiogram QT prolongedInvestigations12/341/313/37
AnemiaBlood and lymphatic system disorders8/341/39/37
ThrombocytopeniaBlood and lymphatic system disorders3/341/34/37
NeutropeniaBlood and lymphatic system disorders1/341/32/37
Decreased appetiteMetabolism and nutrition disorders4/341/35/37
HypotensionVascular disorders1/341/32/37
ConstipationGastrointestinal disorders2/341/33/37

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Initial Dose 30 mg/Day QuizartinibInitial Dose 20 mg/Day QuizartinibTotal
<=18 years000
Between 18 and 65 years15217
>=65 years19120
Age, Continuous
Age, Continuous(years)Initial Dose 30 mg/Day QuizartinibInitial Dose 20 mg/Day QuizartinibTotal
Mean60.2 ± 14.5158.0 ± 9.9260.0 ± 14.68
Sex: Female, Male
Sex: Female, Male(Participants)Initial Dose 30 mg/Day QuizartinibInitial Dose 20 mg/Day QuizartinibTotal
Female22022
Male12315
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Initial Dose 30 mg/Day QuizartinibInitial Dose 20 mg/Day QuizartinibTotal
Hispanic or Latino000
Not Hispanic or Latino34337
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Initial Dose 30 mg/Day QuizartinibInitial Dose 20 mg/Day QuizartinibTotal
Japan34337
BMI
BMI(kg/m^2)Initial Dose 30 mg/Day QuizartinibInitial Dose 20 mg/Day QuizartinibTotal
Mean20.72 ± 2.5322.25 ± 3.3720.84 ± 2.58
FLT3-ITD Status
FLT3-ITD Status(Participants)Initial Dose 30 mg/Day QuizartinibInitial Dose 20 mg/Day QuizartinibTotal
Positive29332
Negative505
Response to Prior Therapy
Response to Prior Therapy(Participants)Initial Dose 30 mg/Day QuizartinibInitial Dose 20 mg/Day QuizartinibTotal
Relapse21324
Refractory13013
08

Study locations

27 sites
  • Aichi, Japan
  • Akita, Japan
  • Chiba, Japan
  • Fukui, Japan
  • Fukuoka, Japan
  • Fukushima, Japan
  • Gifu, Japan
  • Gunma, Japan
  • Hiroshima, Japan
  • Hokkaido, Japan
  • Ibaraki, Japan
  • Kagoshima, Japan
  • Kanagawa, Japan
  • Kyoto, Japan
  • Miyagi, Japan
  • Nagasaki, Japan
  • Nara, Japan
  • Okayama, Japan
  • Osaka, Japan
  • Saga, Japan
  • Saitama, Japan
  • Shizuoka, Japan
  • Tochigi, Japan
  • Tokyo, Japan
  • Toyama, Japan
  • Yamagata, Japan
  • Yamanashi, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Mar 2018, 15 months.

Results were first posted in Feb 2020, 1 year 10 months after primary completion. A results delay was requested in Mar 2019.

Of 57 industry-sponsored phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 55. This study's 15 months is below that.

Counting every sponsor, half of 443 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2016
First posted
Dec 7, 2016
StartActual
Dec 8, 2016
Primary completionActual
Mar 28, 2018
CompletionActual
Sep 14, 2018
Results delay requested
Mar 13, 2019
Results first posted
Feb 17, 2020
Last update
Feb 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02984995
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Dec 7, 2016
Start date
Dec 8, 2016
Primary completion
Mar 28, 2018
Completion
Sep 14, 2018
Results posted
Feb 17, 2020
Last update
Feb 17, 2020

Study contacts

Global Clinical Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Quizartinib

Start the discussion